RCAG
PTLA

Rehmann Capital Advisory Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Rehmann Capital Advisory Group’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$4.53K Buy
169
+63
+59% +$1.77K ﹤0.01% 1236
2019
Q2 		$2.88K Hold
106
– – ﹤0.01% 1702
2019
Q1 		$3.68K Buy
+106
New +$3.06K ﹤0.01% 1608

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Rehmann Capital Advisory Group's PTLA Position: Q3 2019 in Review

Rehmann Capital Advisory Group increased its Portola Pharmaceuticals, Inc. (PTLA) stake by 59% in Q3 2019, buying an estimated $1.77K and bringing the position to 169 shares worth $4.53K. The position accounts for ﹤0.01% of the portfolio, ranked #1236.

Rehmann Capital Advisory Group first reported a position in PTLA in Q1 2019 and has held it in 3 quarters since. 212 funds tracked by Wall St. Rank hold PTLA as of Q3 2019.

  • Rehmann Capital Advisory Group held 169 shares of Portola Pharmaceuticals, Inc. worth $4.53K as of Q3 2019.
  • Rehmann Capital Advisory Group bought 63 Portola Pharmaceuticals, Inc. shares in Q3 2019, an estimated $1.77K.
  • Portola Pharmaceuticals, Inc. made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1236 holding.
  • Rehmann Capital Advisory Group first reported a position in Portola Pharmaceuticals, Inc. in Q1 2019 and has held it in 3 quarters since.
  • 212 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.